2. Why PharmaceuticalThe Pharmaceutical In India is the world third largest in terms ofvolume and stands 14thin terms of values.
3. Why Lupin Lupin is the 4thlargest player in Indian pharmaceuticals industry. It has emerged as an out performer in the Pharma sector. Its Stock counted among frontline farm stock and considered forthe long term buy. The company over the year has grown to be one of the top tengeneric company in the USA, Japan & South African market.
4. About Lupin Lupin Limited is an innovation led transnational pharmaceuticalcompany producing a wide range of quality, affordable generic andbranded formulations. Lupin first gained recognition when it became one of the worldslargest manufacturers of Tuberculosis drugs. Lupin has emerged as the 4th largest and the fastest growing Top 5company in the U.S.A. Began Operations : 1968
5. About LupinBoard of Directors• Dr Desh Bandhu Gupta - Chairman• Dr Kamal K Sharma - Managing Director• Mrs M. D. Gupta - Executive Director• Mrs Vinita Gupta - Director• Mr Nilesh Gupta - Executive Director• Dr Vijay Kelkar - Director• Mr Richard Zahn - Director• Mr R. A. Shah – Director
7. Vision Of The CompanyAn Innovation Led,TransnationalPharmaceutical Company.
8. Mision Of The CompanyOur mission is to become atransnational pharmaceutical companythrough the development andintroduction of a wide portfolio ofbranded and generic products in keymarkets.
9. Values Of The CompanySuperior PerformanceEntrepreneurshipCustomer OrientationWorking TogetherRespect for PeopleIntegrity
10. History & Milestone Of Lupin1968: Lupin started business.1972: Lupin Laboratories Pvt. Ltd was incorporated.1980: Lupin Started a formulations plant and an R&D center atAurangabad (Maharastra).2001: State-of-the-art R&D Centre at Pune was Started.
11. History & Milestone Of Lupin2004 : WHO approval was received for State of the artformulation Plants at Goa and Aurangabad.2009 : Lupin acquired majority stake in MulticarePharmaceuticals Philippines Inc.2011: Lupin Acquires Irom Pharmaceuticals through its JapaneseSubsidiary.
12. Awards-Accolades Of Lupin
13. Awards-Accolades Of Lupin2009 :International Excellence Award by Institute of EconomicStudies.2010 : Best Drug Development Company, Asia by The NewEconomy Pharmaceutical & Healthcare Awards.2010: Lupin wins The Most Promising Entrant into the BigLeague by CNBC India Business Leader Awards.2011: Lupin ranked amongst Indias Top 3 Best Companies toWork For in Healthcare and Pharma Sector.2012: Mrs. Vinita Gupta won the Business Today 30 MostPowerful Women in Business award.
24. Place Lupin has created strong foothold in the advanced marketsof USA , Europe, Japan , Australia and emerging markets ofIndia and some of the other Rest of the world countries..
25. Price Initially the company adopted Cost based pricing strategy but afternew Pharma pricing policy, it has changed its pricing policy. New Pricing Policy New pricing policy is good for the people of India who can buy essentialdrugs at cheaper prices and at the same time it is less taxing for thePharma companies.
26. Promotion Influencing the physician is key to pharmaceutical sales.Physicians are the most important players in pharmaceuticalsales. Eli Lilly India (Lilly) and Lupin ltd announced that theyhave entered into strategic collaboration to promote anddistribute Lilly’s Hum insulin range of products.
27. PESTAL Analysis
28. PESTAL AnalysisPoliticalGovernments have a responsibility to take all necessary measuresto ensure that much-needed new medicines are developed,become available and are accessible.
29. PESTAL AnalysisEconomic Global economic crisis. Reduction in individual income. The economic crisis pressure are seeing an increased growth instrategic buying groups who are forcing down prices.
30. PESTAL AnalysisSocial/CultureThere is also the problem of the increasing obesityamongst the population and its associated health risks.
31. PESTAL AnalysisTechnologicalThe technological advancement creates new business prospectsboth in terms of new therapy systems and service provisions. Theonline opportunities will see the growth in:Customized treatmentSocial media for health careDirect to patient advertisingDirect to patient communication
32. PESTAL AnalysisLegislationThe pharmaceutical industry has many regulatory and legislativerestriction.Changes to advertising laws.Increased litigation.
33. Porter’s five forces Analysis
34. Porter’s five forces AnalysisPower of Buyers Generic (low cost versions of the branded drugs) drugs offercost-effectives to the innovator drugs and thus offer significantsavings for buyers. The bargaining power of buyers is high.
35. Porter’s five forces AnalysisPower of suppliers The barging power is high for API companies with difficult tomanufacture products. These companies command premiumprices. However majority of API suppliers have low bargingpower since they produce products which are simple tomanufacture or commoditized. Thus bargaining power of suppliers as a whole is Medium.
36. Porter’s five forces AnalysisCompetitive Rivalry The growth opportunities for Pharma companies are expected togrow manifold in the next few years with many drugs going offpatent in the US and emerging countries coming into focus. The competitive rivalry is high.
37. Porter’s five forces AnalysisAvailability of substitutes The threat of substitution is higher in unbranded marketswhere one generic can be substituted by another by thepharmacists. The threat of substitute is high.
38. Porter’s five forces AnalysisEntry barriers Entry barriers in the emerging markets are high due to its brandednature. However the companies require extensive legal knowledgecombined with ability to develop the product earlier thancompetition, this is possible for only a few top companies.
61. “Human Resources are something above eachmeasurement. The capacity of these resources can beextended indefinitely when each person begin tothink.”
62. To offer differential skillsets to people forenhancing competitiveedge.
63. Philosophy“To convert employees into leaders in stipulationsof capability to lead self, situation and people.”
64. Recruitment Process
65. Lupin is using three different medium for selecting the right talent:Management Trainee ProgrammeYoung Leaders ProgrammeAdvertisement
66. Learning and Development Lupin has instituted various programs aimed at developingleadership qualities for first line supervisors, mid-sized teamleaders or large function heads. They have developed specific programs in order to groom thistalent pool on individual basis in 3 areas:• Education• Training & Development• Job rotation / exposure
67. Programmer For New Joiners and First-line Supervisors Udbhav The Iceberg Leader Plus Buddy
68. For Managers: AMEX (Accelerating Managerial Excellence) Manufacturing Business Leadership Programme Executive Coaching For Senior Management
69. Performance Appraisal
70. Employee appraisals are a balancing act between theexpectations of employees and the managementsperception of the employees contribution to businessgoals. The Company use Management By Objective Method forPerformance Appraisal. It is a developmental aspect as it involves employeetraining for right fit.
71. Need of HR Specialized employeesIssue:Higher Education Aspirations.Solution:Introduction of the PhD Program at the Lupin Research Park.
72. Whistle Blowing PolicyWhistleblowing encourages and enables employees to raiseserious concerns within the Council rather than overlooking aproblem or blowing the whistle outside.Transparency helps Companies to redefine processes andmake improvements.
73. Corporate Social Responsibility
74. Lupin Human Welfare & ResearchFoundation
75. Milestones of LHWRF Won the FICCI Ladies Organization Award for WomenWelfare. Third Dalmia Environment Award for best watermanagement practices. Award for outstanding achievement in rural development.